Financial StabilityNuvation ended 1Q25 with $461.7M in cash, cash equivalents, and marketable securities, which could provide an operational runway through profitability.
Market PenetrationNuvation expects higher market penetration due to higher mPFS vs peers, CNS efficacy and a better safety profile.
Regulatory ApprovalFull approval in line agnostic ROS1+ NSCLC removes regulatory risks, and focus now turns to commercialization.